The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

NCT05042973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Heart Failure

Interventions

DRUG: Empagliflozin 10 MG
DRUG: Placebo

Sponsor

Jacob Moller

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]